Leerink Partners Initiates Coverage On Nautilus Biotechnology with Outperform Rating, Announces Price Target of $4

Benzinga Newsdesk www.benzinga.com Positive 70.7%

Neg 0% Neu 0% Pos 70.7%

Leerink Partners analyst Puneet Souda initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Outperform rating and announces Price Target of $4.